WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "596bb2de-2340-45ae-8011-96dc33fb2e20"}, "_deposit": {"created_by": 3, "id": "26900", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "26900"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00026900", "sets": ["1763"]}, "author_link": ["22059", "22233", "45455", "640", "458", "45456"], "item_4_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2005-01-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "450", "bibliographicPageStart": "445", "bibliographicVolumeNumber": "31", "bibliographic_titles": [{"bibliographic_title": "医療薬学 = Japanese journal of pharmaceutical health care and sciences"}]}]}, "item_4_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "We examined the influence of basic drugs and protein variants on the binding disposition of ropivacaine to α1-acid glycoprotein (AGP). On doing this, we found the values of the competitive inhibition constant (Ki) for dipyridamole, verapamil, lidocaine and disopyramide with respect to the binding of ropivacaine to commercial AGP (70 mg/dL) to be 2.1, 5.2, 6.0 and 11.0μM, respectively. Also, there was a strong correlation between the fu value and the AGP concentration when ropivacaine was added to plasma samples from ten healthy volunteers (r=0.861). Among the volunteers, eight showed F1S variants and two showed F1 variants without the S variant of AGP. There was no difference in the fu value of ropivacaine between these two groups. However, when ropivacaine was added together with dipyridamole, the fu values of ropivacaine in plasma from volunteers with ES variants were clearly higher than those from volunteers without the S variant. When ropivacaine was added together with disopyramide or lidocaine, however, there was no difference in fu values between these variants. Our results indicate that variability in the effectiveness and/or adverse effects of ropivacaine are caused by changes in fu as a consequence of changes in AGP concentration. They also suggest that in combination therapy, it is also important to consider the AGP variant-dependence of the inhibitory effect of concomitantly administered drugs.", "subitem_description_type": "Abstract"}]}, "item_4_publisher_17": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "日本医療薬学会 = Japanese Society of Pharmaceutical Health Care and Sciences"}]}, "item_4_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.5649/jjphcs.31.445", "subitem_relation_type_select": "DOI"}}]}, "item_4_relation_28": {"attribute_name": "関連URI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.jsphcs.jp/", "subitem_relation_type_select": "URI"}}, {"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.jstage.jst.go.jp/browse/jjphcs/-char/ja", "subitem_relation_type_select": "URI"}}]}, "item_4_rights_23": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Copyright © JSPHCS. 日本医療薬学会 Japanese Society of Pharmaceutical Health Care and Sciences"}]}, "item_4_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AA11527197", "subitem_source_identifier_type": "NCID"}]}, "item_4_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1346-342X", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "石崎, 純子"}], "nameIdentifiers": [{"nameIdentifier": "640", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60401890", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=60401890"}, {"nameIdentifier": "60401890", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000060401890"}]}, {"creatorNames": [{"creatorName": "下村, 祥子"}], "nameIdentifiers": [{"nameIdentifier": "45455", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "福和, 千恵"}], "nameIdentifiers": [{"nameIdentifier": "45456", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "嶋田, 努"}], "nameIdentifiers": [{"nameIdentifier": "458", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "90409384", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=90409384"}, {"nameIdentifier": "90409384", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000090409384"}]}, {"creatorNames": [{"creatorName": "横川, 弘一"}], "nameIdentifiers": [{"nameIdentifier": "22233", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50283122", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000050283122"}]}, {"creatorNames": [{"creatorName": "宮本, 謙一"}], "nameIdentifiers": [{"nameIdentifier": "22059", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "30100514", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000030100514"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-10-05"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "PH-PR-SHIMADA-T-445.pdf", "filesize": [{"value": "995.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 995400.0, "url": {"label": "PH-PR-SHIMADA-T-445.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/26900/files/PH-PR-SHIMADA-T-445.pdf"}, "version_id": "0e67fb30-5076-4aa2-b1b4-bf4ad9bd21a7"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "ropivacaine", "subitem_subject_scheme": "Other"}, {"subitem_subject": "α1-acid glycoprotein", "subitem_subject_scheme": "Other"}, {"subitem_subject": "protein binding", "subitem_subject_scheme": "Other"}, {"subitem_subject": "drug interaction", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "局所麻酔薬ropivacaineのα1-酸性糖タンパク結合動態と薬物間相互作用の検討", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "局所麻酔薬ropivacaineのα1-酸性糖タンパク結合動態と薬物間相互作用の検討"}, {"subitem_title": "Binding Disposition of Local Anesthetic Ropivacaine to .ALPHA.1 -acid Glycoprotein and Interactions with Co-administered Drugs", "subitem_title_language": "en"}]}, "item_type_id": "4", "owner": "3", "path": ["1763"], "permalink_uri": "http://hdl.handle.net/2297/39137", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-10-05"}, "publish_date": "2017-10-05", "publish_status": "0", "recid": "26900", "relation": {}, "relation_version_is_last": true, "title": ["局所麻酔薬ropivacaineのα1-酸性糖タンパク結合動態と薬物間相互作用の検討"], "weko_shared_id": -1}
局所麻酔薬ropivacaineのα1-酸性糖タンパク結合動態と薬物間相互作用の検討
http://hdl.handle.net/2297/39137
http://hdl.handle.net/2297/391370b8acf43-bec5-45de-a13b-66b7cba4024b
名前 / ファイル | ライセンス | アクション |
---|---|---|
PH-PR-SHIMADA-T-445.pdf (995.4 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-10-05 | |||||
タイトル | ||||||
タイトル | 局所麻酔薬ropivacaineのα1-酸性糖タンパク結合動態と薬物間相互作用の検討 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Binding Disposition of Local Anesthetic Ropivacaine to .ALPHA.1 -acid Glycoprotein and Interactions with Co-administered Drugs | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
石崎, 純子
× 石崎, 純子× 下村, 祥子× 福和, 千恵× 嶋田, 努× 横川, 弘一× 宮本, 謙一 |
|||||
書誌情報 |
医療薬学 = Japanese journal of pharmaceutical health care and sciences 巻 31, 号 6, p. 445-450, 発行日 2005-01-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1346-342X | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA11527197 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.5649/jjphcs.31.445 | |||||
出版者 | ||||||
出版者 | 日本医療薬学会 = Japanese Society of Pharmaceutical Health Care and Sciences | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | We examined the influence of basic drugs and protein variants on the binding disposition of ropivacaine to α1-acid glycoprotein (AGP). On doing this, we found the values of the competitive inhibition constant (Ki) for dipyridamole, verapamil, lidocaine and disopyramide with respect to the binding of ropivacaine to commercial AGP (70 mg/dL) to be 2.1, 5.2, 6.0 and 11.0μM, respectively. Also, there was a strong correlation between the fu value and the AGP concentration when ropivacaine was added to plasma samples from ten healthy volunteers (r=0.861). Among the volunteers, eight showed F1S variants and two showed F1 variants without the S variant of AGP. There was no difference in the fu value of ropivacaine between these two groups. However, when ropivacaine was added together with dipyridamole, the fu values of ropivacaine in plasma from volunteers with ES variants were clearly higher than those from volunteers without the S variant. When ropivacaine was added together with disopyramide or lidocaine, however, there was no difference in fu values between these variants. Our results indicate that variability in the effectiveness and/or adverse effects of ropivacaine are caused by changes in fu as a consequence of changes in AGP concentration. They also suggest that in combination therapy, it is also important to consider the AGP variant-dependence of the inhibitory effect of concomitantly administered drugs. | |||||
権利 | ||||||
権利情報 | Copyright © JSPHCS. 日本医療薬学会 Japanese Society of Pharmaceutical Health Care and Sciences | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | http://www.jsphcs.jp/ | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.jstage.jst.go.jp/browse/jjphcs/-char/ja |